539730 FREDUN

Fredun Pharmaceuticals Share Price

 

 

Fredun Pharmaceuticals live price: ₹1820. It opened at ₹1,844 vs previous close ₹1,835; intraday high/low: ₹1,845/₹1,750. The 50 & 200 DMA stand at ₹1,671.72/₹1,452.11.

Fredun Pharmaceuticals Performance

  • Today's Low
  • ₹1,750
  • Today's High
  • ₹1,845
  • 52 Week Low
  • ₹646
  • 52 Week High
  • ₹1,999
  • Open Price₹1,844
  • Previous Close₹1,835
  • Volume6,923
  • 50 DMA₹1,671.72
  • 100 DMA₹1,613.47
  • 200 DMA₹1,452.11

Investment Returns

  • Over 1 Month + 15.37%
  • Over 3 Month + 26.65%
  • Over 6 Month + 28.29%
  • Over 1 Year + 182.13%

Smart Investing Starts Here Start SIP with Fredun Pharmaceuticals for Steady Growth!

Invest Now

Fredun Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 25.5
  • PEG Ratio
  • 0.3
  • Market Cap Cr
  • 867
  • P/B Ratio
  • 5.1
  • Average True Range
  • 88.49
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • 22.47
  • RSI
  • 67.43
  • MFI
  • 67.84

Fredun Pharmaceuticals Financials

Fredun Pharmaceuticals Technicals

EMA & SMA

Current Price
₹1,820.00
-14.75 (-0.8%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹1,710.76
  • 50 Day
  • ₹1,671.72
  • 100 Day
  • ₹1,613.47
  • 200 Day
  • ₹1,452.11

Resistance and Support

1806.17 Pivot Speed
  • R3 1,957.23
  • R2 1,901.07
  • R1 1,862.33
  • S1 1,767.43
  • S2 1,711.27
  • S3 1,672.53

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Fredun Pharmaceuticals has an operating revenue of Rs. 589.35 Cr. on a trailing 12-month basis. An annual revenue growth of 31% is outstanding, Pre-tax margin of 6% is okay, ROE of 14% is good. The company has a reasonable debt to equity of 7%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 10% and 28% from 50DMA and 200DMA. It is currently FORMING a base in its weekly chart and is trading around 5% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 98 which is a GREAT score indicating consistency in earnings, a RS Rating of 96 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 48 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of A is the best. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Fredun Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-09 Quarterly Results
2025-11-08 Quarterly Results
2025-09-25 Preferential Issue of shares & Others To consider 1. Issue Of Warrants. alia, to consider a proposal for fund raising up to Rs.120 crores by way of further public offer, rights issue, debt issue, preferential issue or any other method.
2025-07-30 Quarterly Results
2025-05-30 Audited Results & Dividend
Date Purpose Remarks
2025-09-23 FINAL Rs.0.70 per share(7%)Dividend
2024-09-23 FINAL Rs.0.70 per share(7%)Final Dividend
2023-09-22 FINAL Rs.0.70 per share(7%)Final Dividend
2022-09-15 FINAL Rs.0.70 per share(7%)Final Dividend
View Fredun Pharmaceuticals Dividend History Arrow

Fredun Pharmaceuticals F&O

Fredun Pharmaceuticals Shareholding Pattern

44.17%
1.06%
1.37%
44.59%
8.81%

Fredun Pharmaceuticals FAQs

Fredun Pharmaceuticals share price is ₹1,820 As on 11 April, 2026 | 03:47

The Market Cap of Fredun Pharmaceuticals is ₹866.6 Cr As on 11 April, 2026 | 03:47

The P/E ratio of Fredun Pharmaceuticals is 25.5 As on 11 April, 2026 | 03:47

The PB ratio of Fredun Pharmaceuticals is 5.1 As on 11 April, 2026 | 03:47

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23